Banavali S, Silvestri F, Hulette B, Hurtubise P, Srivastava A, Civin C I, Preisler H D
Barrett Cancer Center, University of Cincinnati, Ohio 45267.
Leuk Res. 1991;15(7):603-8. doi: 10.1016/0145-2126(91)90029-s.
The expression of progenitor cell associated antigen CD34 was investigated in cells from 28 patients with chronic myeloid leukemia (CML). The CD34 positivity varied from 0-26% in patients with chronic phases CML (n = 17); from 6-64% in patients with accelerated phase CML (n = 4); and from 27-97% in the patients with blastic crisis of CML (n = 8). The difference in CD34 positivity between chronic (mean 10.1 +/- 2.3%), accelerated (37.7 +/- 13.3%) and blastic (58.0 +/- 7.3%) phases of CML is statistically significant (p less than 0.05), however, the number of patients studied, especially in accelerated and blastic phases is very small. There was no difference in the CD34 positivity of the cells in the peripheral blood and in the bone marrow. CD34 positivity was higher in patients with chronic phase CML at diagnosis (untreated patients) than in those who were studied during treatment. The possible importance of serially studying CD34 positivity in patients with CML is discussed in the paper.
对28例慢性髓性白血病（CML）患者的细胞进行了祖细胞相关抗原CD34表达的研究。慢性期CML患者（n = 17）的CD34阳性率为0 - 26%；加速期CML患者（n = 4）为6 - 64%；急变期CML患者（n = 8）为27 - 97%。CML慢性期（平均10.1 +/- 2.3%）、加速期（37.7 +/- 13.3%）和急变期（58.0 +/- 7.3%）之间CD34阳性率的差异具有统计学意义（p < 0.05），然而，所研究的患者数量，尤其是加速期和急变期的患者数量非常少。外周血和骨髓中细胞的CD34阳性率没有差异。诊断时（未治疗患者）慢性期CML患者的CD34阳性率高于治疗期间研究的患者。本文讨论了对CML患者连续研究CD34阳性率的可能重要性。
